Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Protagenic Therapeutics ( (PTIX) ) is now available.
On November 3, 2025, Jennifer Chao resigned from the Board of Directors of Protagenic Therapeutics, Inc., with no disagreements reported between her and the company.
Spark’s Take on PTIX Stock
According to Spark, TipRanks’ AI Analyst, PTIX is a Underperform.
Protagenic Therapeutics faces significant financial difficulties, with no revenue and persistent losses. Technical indicators suggest weak market momentum, and the company’s valuation is unattractive due to negative earnings. These factors collectively result in a low overall stock score, reflecting substantial risks and challenges.
To see Spark’s full report on PTIX stock, click here.
More about Protagenic Therapeutics
Average Trading Volume: 2,672,238
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.14M
Learn more about PTIX stock on TipRanks’ Stock Analysis page.